Wasil Khan, MD
Allergy & Immunology · Savannah, GANPI 1104828250
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.7% of the total across 379 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 20.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,119, 4.8 times the $443 reported in 2019.
Across 379 payments — averaging $18.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$1K
- Biocryst US Sales Co., LLC$1K
- AstraZeneca$868
- Pfizer$556
- Takeda Pharmaceuticals U.S.A., Inc.$491
- Regeneron Healthcare Solutions, Inc.$478
- plus $2K from 29 others
What the payments were for
- Consulting fees$260%
- Food & beverage$6,68898%
- Education$1342%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 67 | $1,390 |
| Biocryst US Sales Co., LLC | 116 | $1,257 |
| AstraZeneca | 40 | $868 |
| Pfizer | 27 | $556 |
| Takeda Pharmaceuticals U.S.A., Inc. | 22 | $491 |
| Regeneron Healthcare Solutions, Inc. | 19 | $478 |
| GSK | 19 | $414 |
| Novartis | 11 | $213 |
| Grifols USA, LLC | 8 | $181 |
| Amgen | 6 | $137 |
| Sanofi | 5 | $106 |
| Ionis Pharmaceuticals, Inc. | 4 | $91 |
| Alk-abello, Inc | 5 | $87 |
| Blueprint Medicines Corporation | 3 | $65 |
| Pharming Healthcare, Inc. | 3 | $48 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $38 |
| Cycle Pharmaceuticals Inc | 1 | $38 |
| Dexcom, Inc. | 2 | $31 |
| Kaleo, Inc. | 2 | $29 |
| Octapharma USA, Inc. | 1 | $26 |
| ADMA Biomanufacturing LLC | 1 | $26 |
| Hospira, Inc. | 1 | $25 |
| Optinose US, Inc. | 1 | $25 |
| Genentech USA, Inc. | 1 | $24 |
| Merck | 2 | $24 |
| Boehringer Ingelheim | 1 | $22 |
| Hikma Pharmaceuticals USA | 1 | $22 |
| AbbVie | 1 | $21 |
| Lilly USA, LLC | 1 | $19 |
| Circassia Inc. | 1 | $19 |
| GC Biopharma USA, Inc. | 1 | $18 |
| Exact Sciences | 1 | $17 |
| Shire North American Group Inc | 1 | $15 |
| Mannkind Corporation | 1 | $15 |
| Galderma Laboratories, L.p. | 1 | $14 |
How this compares
$6,848 in reported general payments places this provider in the 60th percentile of 107 allergy & immunology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TakhzyroLanadelumab-Flyo | 13 | $688,644 |
| Dupixent PenDupilumab | 48 | $180,254 |
| XolairOmalizumab | 56 | $164,816 |
| NucalaMepolizumab | 29 | $116,966 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 26 | $114,833 |
| Fasenra PenBenralizumab | 13 | $75,283 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 58 | $47,665 |
| Breo ElliptaFluticasone/Vilanterol | 50 | $21,143 |
| Arnuity ElliptaFluticasone Furoate | 66 | $14,590 |
| Epinephrine | 47 | $10,913 |
| AirsupraAlbuterol Sulfate/Budesonide | 13 | $7,917 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 230 | $5,670 |
| SymbicortBudesonide/Formoterol Fumarate | 18 | $4,906 |
| Pimecrolimus | 16 | $4,690 |
| Ipratropium Bromide | 127 | $4,011 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Takhzyro | $491 | $688,64413 claims |
| GSKNucala, Trelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $414 | $200,366203 claims |
| Grifols USA, LLCGamunex-C | $181 | $114,83326 claims |
| AstraZenecaAirsupra, Symbicort | $868 | $12,82431 claims |
| Hikma Pharmaceuticals USAEpinephrine | $22 | $10,91347 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 107 allergy & immunology providers in Georgia.
Other allergy & immunology in Savannah
- Bruce FinkelSavannah$6K
- Brad GoodmanSavannah$5K
- Monica KenneySavannah$5K
- Michael BlaissRoswell$1.1M
- Deborah BirxAtlanta$470K
- Tracy BridgesAlbany$364K
- Jack EadesMacon$237K
- Stanley FinemanMarietta$186K
- Robert CartwrightColumbus$169K
- Robert ChrzanowskiColumbus$115K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.